Diabetes Control and Complications Trial (DCCT)

Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
Harvard Medical School
.
Chrome 2001
Chrome 2001
.

Diabetes Control and Complications Trial (DCCT)

Diabetes Type 1
35132
Potential Complications of Diabetes
Diabetes Control and Complications Trial (DCCT)
Diabetes Control and Complications Trial (DCCT)
htmDCCT
The DCCT is a clinical study conducted from 1983 to 1993 by the NIDDK. It showed that keeping blood sugar levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes.
202634
National Institute of Health
2008-02-07
t
NIDDK - National Diabetes Information Clearinghouse
2010-02-07

gifNIDDKlogo

Illustration of torso showing circulatory system
Diabetes Control and Complications Trial

What Is the DCCT?
The DCCT is a clinical study conducted from 1983 to 1993 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The study showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. In fact, it demonstrated that any sustained lowering of blood glucose helps, even if the person has a history of poor control.
The largest, most comprehensive diabetes study ever conducted, the DCCT involved 1,441 volunteers with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease.
The study compared the effects of two treatment regimens — standard therapy and intensive control — on the complications of diabetes. Volunteers were randomly assigned to each treatment group.

DCCT Study Findings
Lowering blood glucose reduces risk:
Eye disease
76% reduced risk
Kidney disease
50% reduced risk
Nerve disease
60% reduced risk

How Did Intensive Treatment Affect Diabetic Eye Disease?
All DCCT participants were monitored for diabetic retinopathy, an eye disease that affects the retina. Study results showed that intensive therapy reduced the risk for developing retinopathy by 76 percent. In participants with some eye damage at the beginning of the study, intensive management slowed the progression of the disease by 54 percent.
The retina is the light-sensing tissue at the back of the eye. According to the National Eye Institute, one of the National Institutes of Health, as many as 24,000 persons with diabetes lose their sight each year. In the United States, diabetic retinopathy is the leading cause of blindness in adults under age 65.

How Did Intensive Treatment Affect Diabetic Kidney Disease?
Participants in the DCCT were tested to assess the development of diabetic kidney disease (nephropathy). Findings showed that intensive treatment prevented the development and slowed the progression of diabetic kidney disease by 50 percent.
Diabetic kidney disease is the most common cause of kidney failure in the United States and the greatest threat to life in adults with type 1 diabetes. After having diabetes for 15 years, one-third of people with type 1 diabetes develop kidney disease. Diabetes damages the small blood vessels in the kidneys, impairing their ability to filter impurities from blood for excretion in the urine. Persons with kidney damage must have a kidney transplant or rely on dialysis to cleanse their blood.

How Did Intensive Treatment Affect Diabetic Nerve Disease?
Participants in the DCCT were examined to detect the development of nerve damage (diabetic neuropathy). Study results showed the risk of nerve damage was reduced by 60 percent in persons on intensive treatment.
Diabetic nerve disease can cause pain and loss of feeling in the feet, legs, and fingertips. It can also affect the parts of the nervous system that control blood pressure, heart rate, digestion, and sexual function. Neuropathy is a major contributing factor in foot and leg amputations among people with diabetes.

How Did Intensive Treatment Affect Diabetes-Related Cardiovascular Disease?
DCCT participants were not expected to have many heart-related problems because their average age was only 27 when the study began. Nevertheless, they underwent cardiograms, blood pressure tests, and laboratory tests of blood fat levels to look for signs of cardiovascular disease. The study proved that volunteers on intensive treatment had significantly lower risks of developing high cholesterol, a cause of heart disease.

Elements of Intensive Management in the DCCT
  • Testing blood glucose levels 4 or more times a day
  • Four daily insulin injections or use of an insulin pump
  • Adjustment of insulin doses according to food intake and exercise
  • A diet and exercise plan
  • Monthly visits to a health care team composed of a physician, nurse educator, dietitian, and behavioral therapist.


What Are the Risks of Intensive Treatment?
In the DCCT, the most significant side effect of intensive treatment was an increase in the risk for hypoglycemia (low blood sugar) episodes severe enough to require assistance from another person. Because of this risk, DCCT researchers do not recommend intensive therapy for children under age 13, people with heart disease or advanced complications, older adults, and people with a history of frequent severe hypoglycemia. Persons in the intensive management group also gained a modest amount of weight, suggesting that intensive treatment may not be appropriate for people with diabetes who are overweight. DCCT researchers estimate that intensive management doubles the cost of managing diabetes because of increased visits to a health care professional and the need for more frequent blood testing at home. However, this cost is offset by the reduction in medical expenses related to long-term complications and by the improved quality of life of people with diabetes.

 
Results of the DCCT are reported in the New England Journal of Medicine, 329(14), September 30, 1993.
For reprints of articles related to the DCCT, please contact:
National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892-3560
Phone: 1-800-860-8747 or (301) 654-3327
Fax: (301) 907-8906
Email: ndic@info.niddk.nih.gov

 
National Diabetes Information Clearinghouse
 
1 Information Way
Bethesda, MD 20892-3560
Phone: 1-800-860-8747 or (301) 654-3327
Fax: (301) 907-8906
Email: ndic@info.niddk.nih.gov
 
The National Diabetes Information Clearinghouse (NDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). NIDDK is part of the National Institutes of Health under the U.S. Department of Health and Human Services.
 
Established in 1978, the clearinghouse provides information about diabetes to people with diabetes and to their families, health care professionals, and the public. NDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about diabetes.
 
Publications produced by the clearinghouse are carefully reviewed by both NIDDK scientists and outside experts.
 
This e-text is not copyrighted. The clearinghouse encourages users of this e-pub to duplicate and distribute as many copies as desired.

NIH Publication No. 02-3874
October 2001

Current as of February 7, 2008

 

21060,
diabetes,diabetic,kidney,nerve,blood glucose,cardiovascular,diabetes information,health care,insulin,type 1 diabetes,blood pressure,cardio,diabetic retinopathy,digestive,exercise,eye disease,heart,kidney disease,retina
21060
dmtContent
Last updated February 07, 2008


    Print Printer-friendly format    
   
.
.  
This website is certified by Health On the Net Foundation. Click to verify.
.